In the absence of specific biomarkers for TDP-43 pathology [43], our results support the clinical utility of 18F-FDG-PET, a widely accessible technique, as a biomarker for helping detecting cases with LATE-NC and differentiating them from healthy aging and AD pathology in clinical settings. This evidence concerns the gene TARDBP and Alzheimer disease.